<DOC>
	<DOCNO>NCT02306343</DOCNO>
	<brief_summary>The study open-label , randomize , two-period , one-way crossover study use Meal Tolerance Test ( MTT ) protocol daily life set protocol . The study consist two part . Subject may participate part one part . The first part test effect local heating post prandial glucose level follow bolus in-patient settings.Type I type II diabetic patient basal bolus insulin therapy admit overnight fast meal tolerance test . Subjects inject 0.2 units/kg consume standardized liquid meal . Blood sample glucose insulin measurement take venous line . The study conduct twice ( test ) without ( control ) use InsuPad device . The second part evaluate safety efficacy device use daily life setting . Type I type II diabetic patient enrol study . They require perform least 3 self monitor blood glucose ( SMBG ) measurement . Study length 25 month . Up one month run period , 12 month device ( test ) 12 month without device ( control ) .The subject ask record event hypoglycemia , hyperglycemia adverse event relate diabetes study .</brief_summary>
	<brief_title>Evaluation Effects Heating Vicinity Insulin Delivery Site Experimental Device</brief_title>
	<detailed_description>The effect InsuPad device study use Meal Tolerance Test protocol daily life set protocol . In Meal Tolerance Test protocol subject consume standardized liquid meal take immediately injection insulin bolus ( 0.2 units/kg body weight ) . Each subject go Meal Tolerance Test protocol twice , InsuPad device ( test condition ) without InsuPad device ( control condition ) randomize order . The study start overnight fast stabilization period subject glucose level stabilize 100-150 mg/dl , use I.V glucose solution/oral glucose intravenous insulin administration need . The patient remain stable ( change glucose level &lt; 20mg/dl ) without intervention infusion 30 min prior study . Blood glucose measurement take peripheral venous pre-specified time point . Total follow time 5 hour post meal . Safety limit study 75 mg/dl low limit 300 mg/dl high limit . If subject 's blood glucose level 75 mg/dl glucose solution give orally increase blood glucose level . If subject blood glucose 300 mg/dl iv insulin give reduce blood glucose level . In daily life set protocol subject meet inclusion exclusion criterion enrol study . Study length 25 month . Up one month run period , 12 month device ( test ) 12 month without device ( control ) . Subjects ask perform least 3 blood glucose measurement day . Subjects ask fill logbook measure blood glucose level insulin dos give whole study . Subjects ask report adverse event study . The subject receive tutorial device usage study procedure . The order test control phase randomly select .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Participant age 18 ( include = 18 year ) BMI 18kg/m2 Insulin dependent diabetes use insulin injection Diabetic patient HbA1c value 12 % Participant understand study requirement treatment procedure , willing comply specify followup evaluation provide write Informed Consent studyspecific test procedure perform Pregnancy Breast feed woman Alcohol addiction Had Coronary Artery Bypass Graft , Post Myocardial Infarction active Ischemic heart failure last 3 month prior study date Had cardiovascular accident transient ischemic accident last 12 month prior study Suffer uncontrolled Hypertension ( blood pressure &gt; 165/90 ) Low blood hemoglobin concentration &lt; 9 g/dL female &lt; 12g/dL male ) Low Hematocrit concentration &lt; 36 % ; Abnormal kidney and/ liver function test . ( Creatinine &gt; 2 , liver test &gt; 3 time upper limit normal range ) Psychological incompetence ; Any clinical condition history , seem relevant principle investigator disqualify participant Subjects diminish skin integrity Subjects heat sensitivity Subjects involve planned participate study may interfere data collection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>rapid act insulin</keyword>
	<keyword>insulin injection</keyword>
	<keyword>insulin delivery</keyword>
	<keyword>local heating</keyword>
	<keyword>experimental device</keyword>
	<keyword>pre post meal glucose level</keyword>
</DOC>